ClinicalTrials.gg
CompletedNCT01149421Updated Feb 2, 2015Results posted

A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes

A Phase 2 interventional study of LY2189265 and Placebo in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 76 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-02-02.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
755
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
9th of 54
755 · median 159
Started
2010
with 6 others
Phase 2
5 of 54
none open now
Registered
8th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 9th largest by enrollment, is one of 7 that started in 2010, is one of 5 in phase 2, and was the 8th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is to assess the effects of 2 doses of LY2189265 on blood pressure and heart rate using 24-hour ambulatory blood pressure monitoring (ABPM), in participants with type 2 diabetes mellitus treated with oral antihyperglycemic medications (OAMs).

03

Conditions studied

  • Diabetes Mellitus, Type 2

Keywords

  • Type 2 Diabetes
  • Diabetes
  • Ambulatory Blood Pressure Monitoring
  • ABPM
  • Blood Pressure
  • Heart Rate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 diabetes taking 1 or more oral diabetes medications and have taken these medications for at least 1 month prior to screening
  • Glycosylated () value ≥7% and ≤9.5% at screening
  • Mean blood pressure >90/60 millimeters of mercury (mmHg) and \<140/90 mmHg at screening
  • If treated for hypertension, are taking 3 or less antihypertensive medications and have been taking these medications for at least 1 month prior to screening
  • Stable weight for 3 months prior to screening
  • (BMI) greater than or equal to 23 kilogram-meter squared (kg/m\^2)
  • Willing to wear an ambulatory blood pressure monitoring device for at least 24 hours on multiple occasions
  • Women of must test negative for pregnancy and be willing to use a reliable method of
  • Male participants must use a reliable method of birth control

Exclusion criteria

Exclusion Criteria:

  • Myocardial infarction, stroke, or hospitalization for heart failure within 3 months prior to screening, or heart failure Class III or IV at screening
  • Ongoing or history of frequent intermittent tachyarrhythmia
  • Resting heart rate \<60 beats per minute (bpm) or >100 bpm at screening
  • Work rotating shifts or work during the hours of 2200 to 0700
  • Chronic insulin therapy
  • Use of a glucagon-like peptide 1 (GLP-1) receptor agonist within 3 months prior to screening, or a dipeptidylpeptidase-IV (DPP-IV) inhibitor within 2 weeks prior to screening
  • Nondominant arm circumference >42 centimeter (cm)
  • Use of drugs to promote weight loss
  • Chronic use of systemic
  • Gastric emptying abnormality or bariatric surgery
  • Hepatitis, other liver disease, or (ALT) >3 times the
  • Acute or chronic pancreatitis
  • Severe renal impairment
  • Active disease or uncontrolled endocrine abnormality
  • Self or family history of thyroid cancer, medullary C-cell hyperplasia, or type 2A or 2B multiple endocrine neoplasia
  • Calcitonin value greater than or equal to 20 picograms per milliliter (pg/ml) at screening
  • Transplanted organ except corneal transplants
  • Active or untreated cancer or in remission \<5 years, except skin, in situ cervical, or prostate cancer
  • Sickle-cell disease, hemolytic anemia, or another hematological condition that may interfere with testing
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
755 participants (actual)

Study arms

  • Experimental
    1.5 milligram (mg) LY2189265

    LY2189265: 1.5 milligram (mg), subcutaneous (SC), once weekly (QW)

    Drug: LY2189265

  • Experimental
    0.75 milligram (mg) LY2189265

    LY2189265: 0.75 milligram (mg), subcutaneous (SC), once weekly (QW)

    Drug: LY2189265

  • Placebo comparator
    Placebo

    Placebo: subcutaneous (SC), once weekly (QW)

    Drug: Placebo

Interventions

  • Administered as a subcutaneous injection once weekly for 26 weeks

    Also known as: Dulaglutide

  • DrugPlacebo

    Administered as a subcutaneous injection once weekly for 26 weeks

06

What researchers measure

Primary outcomes

  1. Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)

    Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 weeks

Secondary outcomes

  1. Change From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)

    Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 26 weeks

  2. Change From Baseline to 16 and 26 Weeks in Mean 24-hour Diastolic Blood Pressure (DBP)

    Mean 24-hour diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  3. Change From Baseline to 16 and 26 Weeks in Mean 24-Hour Heart Rate (HR)

    Mean 24-hour heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  4. Change From Baseline to 16 and 26 Weeks in Mean 24-hour Pulse Pressure

    Mean 24-hour pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  5. Change From Baseline to 16 and 26 Weeks in Mean 24-hour Mean Arterial Pressure (MAP)

    Mean 24-hour mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  6. Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Systolic Blood Pressure (SBP)

    Mean daytime and nighttime systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic SBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.

    Time frame: Baseline, 16 and 26 weeks

  7. Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Diastolic Blood Pressure (DBP)

    Mean daytime and nighttime diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic DBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.

    Time frame: Baseline, 16 and 26 weeks

  8. Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Heart Rate (HR)

    Daytime and nighttime heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic HR was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.

    Time frame: Baseline, 16 and 26 weeks

  9. Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Pulse Pressure

    Mean daytime and nighttime pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  10. Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Mean Arterial Pressure (MAP)

    Mean daytime and nighttime mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  11. Change From Baseline to 16 and 26 Weeks in Glycosylated Hemoglobin (HbA1c)

    Glycosylated hemoglobin (HbA1c) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  12. Change From Baseline to 16 and 26 Weeks in Fasting Blood Glucose (FBG)

    Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  13. Percentage of Participants Achieving an Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%

    Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with Chi-squared test/Fisher's exact test.

    Time frame: Baseline and 16 and 26 weeks

  14. Number of Participants With Treatment Emergent Adverse Events at 26 Weeks

    A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  15. Change From Baseline to 16 and 26 Weeks on Pancreatic Enzymes

    Amylase (total and pancreas-derived) and lipase concentrations were measured.

    Time frame: Baseline, 16 and 26 weeks

  16. Change From Baseline to 16 and 26 Weeks on Serum Calcitonin

    Time frame: Baseline, 16 and 26 weeks

  17. Change From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP)

    Time frame: Baseline, 16 weeks

  18. Change From Baseline to 16 and 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

    The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  19. Number of Events of Adjudicated Pancreatitis up to 26 Weeks

    The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  20. Number of Participants With Adjudicated Cardiovascular Events up to 26 Weeks

    Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline through 26 weeks

  21. Anti-LY2189265 Antibodies

    LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 16 and 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (30 weeks). The number of participants with initial postbaseline detection of treatment-emergent (defined as a 4-fold increase in the ADA titer from baseline) anti-drug (LY2189265) ADA at each time point were summarized.

    Time frame: Baseline, 16, 26, and 30 weeks

  22. Rate of Hypoglycemic Episodes

    Hypoglycemic events (HE) were classified as severe (defined as an HE requiring assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as an HE without typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), nocturnal (defined as any HE occurring between bedtime and waking with a measured blood glucose of ≤3.9 mmol/L), or non-nocturnal. Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Logit link. Negative binomial mean was adjusted by treatment, visit, and visit by treatment interaction. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Baseline, 16 and 26 weeks

  23. Change From Baseline to 16 and 26 Weeks in Body Weight

    Least Squares (LS) means was calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

    Time frame: Baseline, 16 and 26 weeks

  24. Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC)

    The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration). Evaluable pharmacokinetic concentrations from the 4, 8, 12, 16, and 26 weeks timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

    Time frame: 4, 8, 12, 16, and 26 weeks

07

Results

Posted Feb 2, 2015

Participant flow

Participant flow — Overall Study
Milestone1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Started251254250
Received at least one dose of study drug251254250
Completed199225206
Not completed522944
Withdrew: Adverse event22611
Withdrew: Withdrawal by subject201213
Withdrew: Sponsor decision011
Withdrew: Lost to follow-up245
Withdrew: Physician decision536
Withdrew: Entry criteria not met112
Withdrew: Protocol violation226

Outcome measures

PrimaryChange From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)

Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)-3.41 ± 0.61-1.70 ± 0.58-0.63 ± 0.59
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: -2.79 · 97.3% CI -4.58 to -1.00
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: -1.07 · 97.3% CI -2.83 to 0.68
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.149 (Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
SecondaryChange From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)

Mean 24-hour systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Change From Baseline to 26 Weeks in Mean 24-hour Systolic Blood Pressure (SBP)-2.51 ± 0.63-1.56 ± 0.600.15 ± 0.62
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: -2.66 · 97.3% CI -4.53 to -0.79
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: -1.71 · 97.3% CI -3.54 to 0.12
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.002 (Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.36 (Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
SecondaryChange From Baseline to 16 and 26 Weeks in Mean 24-hour Diastolic Blood Pressure (DBP)

Mean 24-hour diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)]
Change From Baseline to 16 and 26 Weeks in Mean 24-hour Diastolic Blood Pressure (DBP)
millimeters of mercury (mmHg)]1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean 24-Hour, Week 16-0.23 ± 0.38-0.13 ± 0.37-0.55 ± 0.37
Mean 24-Hour, Week 260.26 ± 0.40-0.09 ± 0.38-0.24 ± 0.39
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 16 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 0.32 · 97.3% CI -0.80 to 1.43
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 16 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 0.42 · 97.3% CI -0.67 to 1.52
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.870 (Treatment comparison at 16 weeks. Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.915 (Treatment comparison at 16 weeks. Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 0.50 · 97.3% CI -0.68 to 1.68
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 0.16 · 97.3% CI -1.00 to 1.31
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.929 (Treatment comparison at 26 weeks. Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.776 (Treatment comparison at 26 weeks. Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
SecondaryChange From Baseline to 16 and 26 Weeks in Mean 24-Hour Heart Rate (HR)

Mean 24-hour heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline to 16 and 26 Weeks in Mean 24-Hour Heart Rate (HR)
beats per minute (bpm)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean 24-Hour HR, Week 163.70 ± 0.452.48 ± 0.430.86 ± 0.44
Mean 24-Hour HR, Week 264.18 ± 0.471.94 ± 0.460.68 ± 0.47
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.556 (Treatment comparison at 16 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 2.84 · 97.3% CI 1.52 to 4.16
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.018 (Treatment comparison at 16 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 1.62 · 97.3% CI 0.32 to 2.92
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 1.00 (Treatment comparison at 16 weeks. Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.904 (Treatment comparison at 26 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 3.50 · 97.3% CI 2.10 to 4.91
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.005 (Treatment comparison at 26 weeks. P-value reported for non-inferior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.) · Least squares mean difference: 1.26 · 97.3% CI -0.13 to 2.64
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.996 (Treatment comparison at 26 weeks. Since non-inferiority was confirmed, superiority analysis was pursued. P-value reported for superior to Placebo. The adjustment for multiplicity was based on a tree-gatekeeping testing strategy.)
SecondaryChange From Baseline to 16 and 26 Weeks in Mean 24-hour Pulse Pressure

Mean 24-hour pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 16 and 26 Weeks in Mean 24-hour Pulse Pressure
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean 24-Hour PP, Week 16-3.07 ± 0.36-1.60 ± 0.35-0.02 ± 0.36
Mean 24-Hour PP, Week 26-2.64 ± 0.38-1.53 ± 0.370.46 ± 0.37
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 16 weeks.) · Mean difference (final values): -3.05 · 95% CI -4.00 to -2.09
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.001 (Treatment comparison at 16 weeks.) · Mean difference (final values): -1.58 · 95% CI -2.51 to -0.64
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks.) · Mean difference (final values): -3.10 · 95% CI -4.10 to -2.09
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks.) · Mean difference (final values): -1.99 · 95% CI -2.98 to -1.00
SecondaryChange From Baseline to 16 and 26 Weeks in Mean 24-hour Mean Arterial Pressure (MAP)

Mean 24-hour mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 16 and 26 Weeks in Mean 24-hour Mean Arterial Pressure (MAP)
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Week 16-1.31 ± 0.43-0.65 ± 0.42-0.60 ± 0.42
Week 26-0.74 ± 0.44-0.57 ± 0.42-0.15 ± 0.43
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.218 (Treatment comparison at 16 weeks.) · Mean difference (final values): -0.71 · 95% CI -1.84 to 0.42
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.931 (Treatment comparison at 16 weeks.) · Mean difference (final values): -0.05 · 95% CI -1.16 to 1.06
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.315 (Treatment comparison at 26 weeks.) · Mean difference (final values): -0.58 · 95% CI -1.72 to 0.55
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.465 (Treatment comparison at 26 weeks.) · Mean difference (final values): -0.42 · 95% CI -1.54 to 0.70
SecondaryChange From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Systolic Blood Pressure (SBP)

Mean daytime and nighttime systolic blood pressure (SBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic SBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Systolic Blood Pressure (SBP)
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean Daytime SBP, Week 16 (n=247, n=251, n=249)-3.67 ± 0.66-1.57 ± 0.63-0.34 ± 0.64
Mean Daytime SBP, Week 26 (n=247, n=251, n=249)-2.52 ± 0.68-1.47 ± 0.650.35 ± 0.67
Mean Nighttime SBP, Week 16 (n=247, n=251, n=249)-2.32 ± 0.76-1.23 ± 0.73-1.08 ± 0.74
Mean Nighttime SBP, Week 26 (n=247, n=251, n=249)-2.40 ± 0.75-1.43 ± 0.72-0.05 ± 0.73
Mean Clinic SBP, Week 16 (n=251, n=254, n=250)-2.33 ± 0.75-1.26 ± 0.72-0.73 ± 0.73
Mean Clinic SBP, Week 26 (n=251, n=254, n=250)-2.29 ± 0.77-0.74 ± 0.740.40 ± 0.75
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean daytime systolic blood pressure (SBP) at 16 weeks.) · Mean difference (final values): -3.33 · 95% CI -5.04 to -1.61
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.153 (Treatment comparison of mean daytime systolic blood pressure (SBP) at 16 weeks.) · Mean difference (final values): -1.23 · 95% CI -2.91 to 0.46
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.002 (Treatment comparison of mean daytime systolic blood pressure (SBP) at 26 weeks.) · Mean difference (final values): -2.87 · 95% CI -4.66 to -1.09
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.042 (Treatment comparison of mean daytime systolic blood pressure (SBP) at 26 weeks.) · Mean difference (final values): -1.82 · 95% CI -3.57 to -0.07
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.221 (Treatment comparison of mean nighttime systolic blood pressure (SBP) at 16 weeks.) · Mean difference (final values): -1.24 · 95% CI -3.23 to 0.75
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.884 (Treatment comparison of mean nighttime systolic blood pressure (SBP) at 16 weeks.) · Mean difference (final values): -0.15 · 95% CI -2.10 to 1.81
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.19 (Treatment comparison of mean nighttime systolic blood pressure (SBP) at 26 weeks.) · Mean difference (final values): -2.35 · 95% CI -4.31 to -0.39
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.159 (Treatment comparison of mean nighttime systolic blood pressure (SBP) at 26 weeks.) · Mean difference (final values): -1.38 · 95% CI -3.31 to 0.54
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.122 (Treatment comparison of mean clinic systolic blood pressure (SBP) at 16 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.601 (Treatment comparison of mean clinic systolic blood pressure (SBP) at 16 weeks.)
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.012 (Treatment comparison of mean clinic systolic blood pressure (SBP) at 26 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.274 (Treatment comparison of mean clinic systolic blood pressure (SBP) at 26 weeks.)
SecondaryChange From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Diastolic Blood Pressure (DBP)

Mean daytime and nighttime diastolic blood pressure (DBP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means of change from baseline was analyzed using mixed model repeated measures (MMRM) adjusted by baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic DBP was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Diastolic Blood Pressure (DBP)
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean Daytime DBP, Week 16 (n=247, n=251, n=249)-0.09 ± 0.430.14 ± 0.41-0.30 ± 0.42
Mean Daytime DBP, Week 26 (n=247, n=251, n=249)0.52 ± 0.430.08 ± 0.41-0.07 ± 0.42
Mean Nighttime DBP, Week 16 (n=247, n=251, n=249)-0.01 ± 0.49-0.28 ± 0.48-1.10 ± 0.48
Mean Nighttime DBP, Week 26 (n=247, n=251, n=249)-0.22 ± 0.51-0.42 ± 0.50-0.69 ± 0.51
Mean Clinic DBP, Week 16 (n=251, n=254, n=250)-0.21 ± 0.520.76 ± 0.50-0.21 ± 0.51
Mean Clinic DBP, Week 26 (n=251, n=254, n=250)0.59 ± 0.500.69 ± 0.480.61 ± 0.49
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.717 (Treatment comparison of mean daytime diastolic blood pressure (DBP) at 16 weeks.) · Mean difference (final values): 0.21 · 95% CI -0.91 to 1.32
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.427 (Treatment comparison of mean daytime diastolic blood pressure (DBP) at 16 weeks.) · Mean difference (final values): 0.44 · 95% CI -0.65 to 1.54
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.300 (Treatment comparison of mean daytime diastolic blood pressure (DBP) at 26 weeks.) · Mean difference (final values): 0.60 · 95% CI -0.53 to 1.73
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.788 (Treatment comparison of mean daytime diastolic blood pressure (DBP) at 26 weeks.) · Mean difference (final values): 0.15 · 95% CI -0.96 to 1.26
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.098 (Treatment comparison of mean nighttime diastolic blood pressure (DBP) at 16 weeks.) · Mean difference (final values): 1.08 · 95% CI -0.20 to 2.37
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.203 (Treatment comparison of mean nighttime diastolic blood pressure (DBP) at 16 weeks.) · Mean difference (final values): 0.82 · 95% CI -0.44 to 2.08
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.493 (Treatment comparison of mean nighttime diastolic blood pressure (DBP) at 26 weeks.) · Mean difference (final values): 0.47 · 95% CI -0.88 to 1.82
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.692 (Treatment comparison of mean nighttime diastolic blood pressure (DBP) at 26 weeks.) · Mean difference (final values): 0.27 · 95% CI -1.06 to 1.60
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.990 (Treatment comparison of mean clinic diastolic blood pressure (DBP) at 16 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.173 (Treatment comparison of mean clinic diastolic blood pressure (DBP) at 16 weeks.)
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.972 (Treatment comparison of mean clinic diastolic blood pressure (DBP) at 26 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.904 (Treatment comparison of mean clinic diastolic blood pressure (DBP) at 26 weeks.)
SecondaryChange From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Heart Rate (HR)

Daytime and nighttime heart rate (HR) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Heart rate measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension. Clinic HR was measured in the clinic using the Omron HEM 907XL Blood Pressure monitor.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · beats per minute (bpm)
Change From Baseline to 16 and 26 Weeks in Mean Daytime, Nighttime, and Clinic Heart Rate (HR)
beats per minute (bpm)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean Daytime HR, Week 16 (n=247, n=251, n=249)3.56 ± 0.502.22 ± 0.491.07 ± 0.49
Mean Daytime HR, Week 26 (n=247, n=251, n=249)4.24 ± 0.511.59 ± 0.490.67 ± 0.50
Mean Nighttime HR, Week 16 (n=247, n=251, n=249)4.60 ± 0.513.43 ± 0.490.65 ± 0.50
Mean Nighttime HR, Week 26 (n=247, n=251, n=249)4.76 ± 0.573.01 ± 0.540.77 ± 0.55
Mean Clinic HR, Week 16 (n=251, n=254, n=250)3.97 ± 0.492.11 ± 0.480.46 ± 0.48
Mean Clinic HR, Week 26 (n=251, n=254, n=250)4.89 ± 0.541.93 ± 0.52-0.11 ± 0.53
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean daytime heart rate (HR) at 16 weeks.) · Mean difference (final values): 2.49 · 95% CI 1.17 to 3.80
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.080 (Treatment comparison of mean daytime heart rate (HR) at 16 weeks.) · Mean difference (final values): 1.15 · 95% CI -0.14 to 2.45
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean daytime heart rate (HR) at 26 weeks.) · Mean difference (final values): 3.57 · 95% CI 2.23 to 4.91
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.168 (Treatment comparison of mean daytime heart rate (HR) at 26 weeks.) · Mean difference (final values): 0.92 · 95% CI -0.39 to 2.24
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean nighttime heart rate (HR) at 16 weeks.) · Mean difference (final values): 3.95 · 95% CI 2.62 to 5.28
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean nighttime heart rate (HR) at 16 weeks.) · Mean difference (final values): 2.78 · 95% CI 1.47 to 4.09
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean nighttime heart rate (HR) at 26 weeks.) · Mean difference (final values): 3.98 · 95% CI 2.49 to 5.47
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.003 (Treatment comparison of mean nighttime heart rate (HR) at 26 weeks.) · Mean difference (final values): 2.24 · 95% CI 0.78 to 3.70
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean clinic heart rate (HR) at 16 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.014 (Treatment comparison of mean clinic heart rate (HR) at 16 weeks.)
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean clinic heart rate (HR) at 26 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.005 (Treatment comparison of mean clinic heart rate (HR) at 26 weeks.)
SecondaryChange From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Pulse Pressure

Mean daytime and nighttime pulse pressure (PP) was measured by using a 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Pulse pressure (PP) measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Pulse Pressure
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean Daytime PP, Week 16-3.46 ± 0.40-1.76 ± 0.380.01 ± 0.39
Mean Daytime PP, Week 26-2.90 ± 0.42-1.62 ± 0.410.51 ± 0.42
Mean Nighttime PP, Week 16-2.23 ± 0.45-0.92 ± 0.430.02 ± 0.44
Mean Nighttime PP, Week 26-2.09 ± 0.43-0.96 ± 0.410.65 ± 0.42
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean daytime pulse pressure (PP) at 16 weeks.) · Mean difference (final values): -3.47 · 95% CI -4.50 to -2.43
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean daytime pulse pressure (PP) at 16 weeks.) · Mean difference (final values): -1.77 · 95% CI -2.79 to -0.75
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean daytime pulse pressure (PP) at 26 weeks.) · Mean difference (final values): -3.40 · 95% CI -4.52 to -2.28
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean daytime pulse pressure (PP) at 26 weeks.) · Mean difference (final values): -2.13 · 95% CI -3.23 to -1.03
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean nighttime pulse pressure (PP) at 16 weeks.) · Mean difference (final values): -2.25 · 95% CI -3.43 to -1.07
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.113 (Treatment comparison of mean nighttime pulse pressure (PP) at 16 weeks.) · Mean difference (final values): -0.93 · 95% CI -2.09 to 0.22
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison of mean nighttime pulse pressure (PP) at 26 weeks.) · Mean difference (final values): -2.74 · 95% CI -3.86 to -1.62
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.004 (Treatment comparison of mean nighttime pulse pressure (PP) at 26 weeks.) · Mean difference (final values): -1.61 · 95% CI -2.72 to -0.51
SecondaryChange From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Mean Arterial Pressure (MAP)

Mean daytime and nighttime mean arterial pressure (MAP) was measured by a using 24-hour ambulatory blood pressure monitoring (ABPM) device attached to the participant's nondominant arm. Ambulatory blood pressure measurements were recorded every 20 minutes during the daytime (0700 to 2200 hours) and every 30 minutes during the nighttime hours (2200 to 0700), as preprogrammed into the device. For statistical analyses, diurnal hours were defined as 0800 to 2100 and nocturnal hours were defined as 0000 to 0600. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimeters of mercury (mmHg)
Change From Baseline to 16 and 26 Weeks in Mean Daytime and Nighttime Mean Arterial Pressure (MAP)
millimeters of mercury (mmHg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Mean Daytime MAP, Week 16-1.30 ± 0.48-0.42 ± 0.46-0.33 ± 0.47
Mean Daytime MAP, Week 26-0.51 ± 0.49-0.42 ± 0.470.05 ± 0.48
Mean Nighttime MAP, Week 16-0.80 ± 0.56-0.59 ± 0.53-1.11 ± 0.54
Mean Nighttime MAP, Week 26-0.96 ± 0.57-0.76 ± 0.54-0.50 ± 0.56
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.128 (Treatment comparison of mean daytime mean arterial pressure (MAP) at 16 weeks.) · Mean difference (final values): -0.97 · 95% CI -2.22 to 0.28
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.883 (Treatment comparison of mean daytime mean arterial pressure (MAP) at 16 weeks.) · Mean difference (final values): -0.09 · 95% CI -1.32 to 1.13
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.390 (Treatment comparison of mean daytime mean arterial pressure (MAP) at 26 weeks.) · Mean difference (final values): -0.56 · 95% CI -1.84 to 0.72
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.463 (Treatment comparison of mean daytime mean arterial pressure (MAP) at 26 weeks.) · Mean difference (final values): -0.47 · 95% CI -1.72 to 0.79
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.671 (Treatment comparison of mean nighttime mean arterial pressure (MAP) at 16 weeks.) · Mean difference (final values): 0.31 · 95% CI -1.13 to 1.76
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.471 (Treatment comparison of mean nighttime mean arterial pressure (MAP) at 16 weeks.) · Mean difference (final values): 0.52 · 95% CI -0.90 to 1.95
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.543 (Treatment comparison of mean nighttime mean arterial pressure (MAP) at 26 weeks.) · Mean difference (final values): -0.46 · 95% CI -1.95 to 1.03
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.728 (Treatment comparison of mean nighttime mean arterial pressure (MAP) at 26 weeks.) · Mean difference (final values): -0.26 · 95% CI -1.72 to 1.20
SecondaryChange From Baseline to 16 and 26 Weeks in Glycosylated Hemoglobin (HbA1c)

Glycosylated hemoglobin (HbA1c) is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · percentage of HbA1c
Change From Baseline to 16 and 26 Weeks in Glycosylated Hemoglobin (HbA1c)
percentage of HbA1c1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Week 16-1.18 ± 0.06-1.04 ± 0.05-0.06 ± 0.05
Week 26-1.01 ± 0.07-0.89 ± 0.06-0.02 ± 0.06
SecondaryChange From Baseline to 16 and 26 Weeks in Fasting Blood Glucose (FBG)

Fasting blood glucose (FBG) is a test to determine how much glucose (sugar) is in a blood sample after an overnight fast. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Change From Baseline to 16 and 26 Weeks in Fasting Blood Glucose (FBG)
millimoles per liter (mmol/L)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Week 16-2.05 ± 0.13-1.94 ± 0.13-0.30 ± 0.13
Week 26-1.67 ± 0.15-1.66 ± 0.150.00 ± 0.15
SecondaryPercentage of Participants Achieving an Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%

Percentages of participants who achieved glycosylated hemoglobin (HbA1c) levels of \<7% or ≤6.5% were analyzed with Chi-squared test/Fisher's exact test.

Time frame:
Baseline and 16 and 26 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Glycosylated Hemoglobin (HbA1c) of <7% or ≤6.5%
percentage of participants1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
HbA1c levels <7.0%, Baseline6.86.78.0
HbA1c levels ≤6.5%, Baseline0.00.40.4
HbA1c levels <7.0%, Week 16 (n=216, n=234, n=225)66.759.012.9
HbA1c levels ≤6.5%, Week 16 (n=216, n=234, n=225)45.836.86.2
HbA1c levels <7.0%, Week 26 (n=206, n=226, n=210)62.154.914.3
HbA1c levels ≤6.5%, Week 26 (n=206, n=226, n=210)38.835.85.2
SecondaryNumber of Participants With Treatment Emergent Adverse Events at 26 Weeks

A treatment-emergent adverse event (TEAE) was defined as an event that first occurs or worsens (increases in severity) after baseline regardless of causality or severity. The number of participants with one or more TEAE is summarized cumulatively at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants With Treatment Emergent Adverse Events at 26 Weeks
participants1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Number of Participants With Treatment Emergent Adverse Events at 26 Weeks160156162
SecondaryChange From Baseline to 16 and 26 Weeks on Pancreatic Enzymes

Amylase (total and pancreas-derived) and lipase concentrations were measured.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Median · units per liter
Change From Baseline to 16 and 26 Weeks on Pancreatic Enzymes
units per liter1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Amylase, Total, Week 16 (n=214, 227, 224)6.00 (-2.00 to 13.00)5.00 (-3.00 to 14.00)0.00 (-6.00 to 7.00)
Amylase, Total, Week 26 (n=205, 220, 209)7.00 (-2.00 to 16.00)4.00 (-2.00 to 15.50)0.00 (-5.00 to 6.00)
Amylase, Pancreas-derived, Wk 16 (n=213, 227, 224)4.00 (0.00 to 9.00)3.00 (-1.00 to 9.00)1.00 (-3.50 to 4.00)
Amylase, Pancreas-derived, Wk 26 (n=204, 220, 209)5.00 (1.00 to 10.00)3.50 (0.00 to 9.50)1.00 (-3.00 to 4.00)
Lipase, Week 16 (n=214, 227, 224)4.00 (-2.00 to 14.00)3.00 (-4.00 to 12.00)-1.00 (-7.00 to 6.00)
Lipase, Week 26 (n=205, 220, 209)6.00 (-1.00 to 14.00)5.00 (-3.00 to 13.00)0.00 (-6.00 to 5.00)
SecondaryChange From Baseline to 16 and 26 Weeks on Serum Calcitonin
Time frame:
Baseline, 16 and 26 weeks
Reported as:
Mean · picograms per milliliter (pg/mL)
Change From Baseline to 16 and 26 Weeks on Serum Calcitonin
picograms per milliliter (pg/mL)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Week 16 (n=213, n=223, n=223)-0.30 ± 1.87-0.03 ± 1.81-0.39 ± 1.24
Week 26 (n=202, n=220, n=209)-0.19 ± 1.730.02 ± 2.04-0.05 ± 2.38
SecondaryChange From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP)
Time frame:
Baseline, 16 weeks
Reported as:
Mean · milligram per liter (mg/L)
Change From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP)
milligram per liter (mg/L)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Change From Baseline to 16 Weeks in High-Sensitivity C-Reactive Protein (Hs-CRP)-0.79 ± 4.91-0.20 ± 7.960.29 ± 6.73
SecondaryChange From Baseline to 16 and 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval

The QT interval is a measure of the time between the start of the Q wave and the end of the T wave and was calculated from electrocardiogram (ECG) data using Fridericia's formula: QTc = QT/RR\^0.33. Corrected QT (QTc) is the QT interval corrected for heart rate and RR, which is the interval between two R waves. PR is the interval between the P wave and the QRS complex. Least Squares (LS) means were calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · milliseconds (msec)
Change From Baseline to 16 and 26 Weeks on Electrocardiogram Parameters, Fridericia Corrected QT (QTcF) Interval and PR Interval
milliseconds (msec)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
QTcF Interval, Week 16 (n=248, n=250, n=246)-2.31 ± 0.97-0.96 ± 0.911.06 ± 0.93
QTcF Interval, Week 26 (n=248, n=250, n=246)-1.73 ± 0.96-0.93 ± 0.921.26 ± 0.94
PR Interval, Week 16 (n=248, n=250, n=244)4.96 ± 0.983.67 ± 0.920.01 ± 0.95
PR Interval, Week 26 (n=248, n=250, n=244)3.32 ± 0.863.17 ± 0.81-1.98 ± 0.84
SecondaryNumber of Events of Adjudicated Pancreatitis up to 26 Weeks

The number of adjudicated (by an independent Clinical Endpoint Committee \[CEC\]) pancreatic events is summarized at 26 weeks. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Number · events
Number of Events of Adjudicated Pancreatitis up to 26 Weeks
events1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Number of Events of Adjudicated Pancreatitis up to 26 Weeks000
SecondaryNumber of Participants With Adjudicated Cardiovascular Events up to 26 Weeks

Deaths and nonfatal cardiovascular adverse events (AEs) were adjudicated by a committee of physicians with cardiology expertise external to the Sponsor. The nonfatal cardiovascular AEs to be adjudicated include myocardial infarction, hospitalization for unstable angina, hospitalization for heart failure, coronary interventions (such as coronary artery bypass graft or percutaneous coronary intervention), and cerebrovascular events including cerebrovascular accident (stroke) and transient ischemic attack. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline through 26 weeks
Reported as:
Number · participants
Number of Participants With Adjudicated Cardiovascular Events up to 26 Weeks
participants1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Any cardiovascular event114
Any fatal cardiovascular event000
Any non-fatal cardiovascular event114
SecondaryAnti-LY2189265 Antibodies

LY2189265 anti-drug antibodies (ADA) were assessed at baseline, 16 and 26 weeks, and at the safety follow-up visit 4 weeks after study drug discontinuation (30 weeks). The number of participants with initial postbaseline detection of treatment-emergent (defined as a 4-fold increase in the ADA titer from baseline) anti-drug (LY2189265) ADA at each time point were summarized.

Time frame:
Baseline, 16, 26, and 30 weeks
Reported as:
Number · participants
Anti-LY2189265 Antibodies
participants1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Week 16200
Week 26130
Week 30010
SecondaryRate of Hypoglycemic Episodes

Hypoglycemic events (HE) were classified as severe (defined as an HE requiring assistance of another person to actively administer resuscitative actions), documented symptomatic (defined as an HE with typical symptoms of hypoglycemia and a blood glucose level of ≤3.9 millimoles per liter \[mmol/L\]), asymptomatic (defined as an HE without typical symptoms of hypoglycemia but with a measured blood glucose of ≤3.9 mmol/L), nocturnal (defined as any HE occurring between bedtime and waking with a measured blood glucose of ≤3.9 mmol/L), or non-nocturnal. Hypoglycemia rate per 30 days was summarized at each visit by treatment group. The rate of hypoglycemia was analyzed using a generalized estimation equations model with a negative binomial distribution and a Logit link. Negative binomial mean was adjusted by treatment, visit, and visit by treatment interaction. A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Mean · events per participant per 30 days
Rate of Hypoglycemic Episodes
events per participant per 30 days1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Severe0 ± 00 ± 00 ± 0
Documented Symptomatic0.14 ± 0.430.16 ± 0.590.08 ± 0.39
Asymptomatic0.17 ± 0.890.15 ± 0.590.06 ± 0.25
Nocturnal0.06 ± 0.300.12 ± 0.640.03 ± 0.22
Non-nocturnal0.29 ± 0.970.26 ± 0.700.15 ± 0.44
SecondaryChange From Baseline to 16 and 26 Weeks in Body Weight

Least Squares (LS) means was calculated using mixed model repeated measures (MMRM) adjusting for baseline, pooled sites, treatment, visit, treatment-by-visit interaction, and the stratified variable of diagnosis of hypertension.

Time frame:
Baseline, 16 and 26 weeks
Reported as:
Least squares mean · kilogram (kg)
Change From Baseline to 16 and 26 Weeks in Body Weight
kilogram (kg)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Week 16-1.84 ± 0.18-0.83 ± 0.18-0.13 ± 0.18
Week 26-1.85 ± 0.23-0.86 ± 0.22-0.08 ± 0.22
Statistical analysis
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 16 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.005 (Treatment comparison at 16 weeks.)
  • 1.5 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = <0.001 (Treatment comparison at 26 weeks.)
  • 0.75 Milligram (mg) LY2189265 vs Placebo · Mixed Models Analysis · p = 0.012 (Treatment comparison at 26 weeks.)
SecondaryMeasurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC)

The population mean estimates and standard deviations were calculated for pharmacokinetic parameters (area under the concentration time curve \[AUC\] at steady state from time zero to 168 hours after study drug administration). Evaluable pharmacokinetic concentrations from the 4, 8, 12, 16, and 26 weeks timepoints were combined and utilized in a population approach to determine the population mean estimate and standard deviation at steady-state.

Time frame:
4, 8, 12, 16, and 26 weeks
Reported as:
Mean · nanograms*hour per liter (ng*h/L)
Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC)
nanograms*hour per liter (ng*h/L)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265
Measurement of LY2189265 Drug Concentration for Pharmacokinetics - Area Under the Concentration Time Curve (AUC)11208 ± 37445998 ± 2003

Adverse events

Non-serious events are listed at a 4% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1.5 Milligram (mg) LY2189265—12/251 (4.8%)164/251 (65.3%)
0.75 Milligram (mg) LY2189265—8/254 (3.1%)161/254 (63.4%)
Placebo—8/250 (3.2%)163/250 (65.2%)
Most frequent serious events
Showing 10 of 31
Most frequent serious events
Event1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
Uterine dilation and curettageSurgical and medical procedures0/1210/1231/119
PregnancyPregnancy, puerperium and perinatal conditions1/1210/1230/119
CholelithiasisHepatobiliary disorders2/2510/2540/250
Benign prostatic hyperplasiaReproductive system and breast disorders0/1300/1311/131
Coronary artery diseaseCardiac disorders0/2510/2541/250
Ventricular tachycardiaCardiac disorders0/2510/2541/250
GranulomaGeneral disorders0/2510/2541/250
DiverticulitisInfections and infestations0/2510/2541/250
Septic shockInfections and infestations0/2510/2541/250
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2510/2541/250
Most frequent other events
Showing 10 of 15
Most frequent other events
Event1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265Placebo
NauseaGastrointestinal disorders35/25118/25416/250
DiarrhoeaGastrointestinal disorders31/25124/25420/250
HeadacheNervous system disorders25/25121/25425/250
NasopharyngitisInfections and infestations23/25119/25424/250
VomitingGastrointestinal disorders19/25111/25411/250
Decreased appetiteMetabolism and nutrition disorders17/2519/2543/250
DyspepsiaGastrointestinal disorders11/25115/2546/250
Back painMusculoskeletal and connective tissue disorders9/25112/25413/250
DizzinessNervous system disorders13/25110/2547/250
Upper respiratory tract infectionInfections and infestations7/2518/25412/250

Baseline characteristics

Participants who received at least one dose of LY2189265 or Placebo.

Age, Continuous
Age, Continuous(years)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
Mean55.96 ± 10.1457.05 ± 10.1756.43 ± 10.5056.48 ± 10.27
Sex: Female, Male
Sex: Female, Male(Participants)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
Female121123119363
Male130131131392
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
Hispanic or Latino9510191287
Not Hispanic or Latino156153159468
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
American Indian or Alaska Native2002
Asian22242369
Native Hawaiian or Other Pacific Islander0011
Black or African American23212266
White201204203608
More than one race3519
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
United States132137139408
Czech Republic12121337
Puerto Rico12141440
Canada34323096
Argentina29282582
Brazil86721
Denmark911828
India15141443
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms/square meters (kg/m^2))1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
Mean32.80 ± 5.6632.55 ± 5.8633.53 ± 6.4932.96 ± 6.02
Glycosylated Hemoglobin (HbA1c)
Glycosylated Hemoglobin (HbA1c)(percentage of glycosylated hemoglobin)1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
Mean7.93 ± 0.767.91 ± 0.737.94 ± 0.787.93 ± 0.76
Body Weight
Body Weight(kilogram (kg))1.5 Milligram (mg) LY21892650.75 Milligram (mg) LY2189265PlaceboTotal
Mean90.42 ± 18.5890.45 ± 18.7493.90 ± 21.2691.58 ± 19.60

4 further baseline measures are reported on the registry.

08

Study locations

76 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phoenix, Arizona 85013, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Anaheim, California 92801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Greenbrae, California 94904, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Lancaster, California 93534, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Los Angeles, California 90057, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sacramento, California 95825, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Spring Valley, California 91978, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coral Gables, Florida 33134, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Daytona Beach, Florida 32114, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Orlando, Florida 32806, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tampa, Florida 33613, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winter Haven, Florida 33880, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cartersville, Georgia 30121, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Gainesville, Georgia 30501, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tucker, Georgia 30084, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96814, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Idaho Falls, Idaho 83404, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bloomington, Indiana 47403, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indianapolis, Indiana 46260, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Louisville, Kentucky 40217, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Paducah, Kentucky 42001, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Metairie, Louisiana 70006, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Auburn, Maine 04210, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Columbia, Maryland 21045, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Haverhill, Massachusetts 01830, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Springfield, Massachusetts 01199, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Detroit, Michigan 48201, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jackson, Mississippi 39216, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jefferson City, Missouri 65109, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Louis, Missouri 63141, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Omaha, Nebraska 68124, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Albuquerque, New Mexico 87106, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Garden City, New York 11530, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dayton, Ohio 45439, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jefferson Hills, Pennsylvania 15022, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Johnstown, Pennsylvania 15905, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Austin, Texas 78728, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Georgetown, Texas 78626, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Houston, Texas 77034, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Salt Lake City, Utah 84124, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Renton, Washington 98057, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, Washington 98664, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, 1657, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Caba, C1050AAK, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mar Del Plata, B7600FZN, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mendoza, 5500, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santa Fe, 3000, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio De Janeiro, 22271-100, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    São Paulo, 04020-041, Brazil
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, Alberta T2H 2G4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Red Deer, Alberta T4N 6V7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vancouver, British Columbia V6H 3X8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Victoria, British Columbia V8V 3N7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Winnipeg, Manitoba R3P 3P4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    St Johns, Newfoundland and Labrador A1B 3V6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamilton, Ontario L8L 2X2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oakville, Ontario L6H 3P1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Toronto, Ontario M4G 3E8, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Laval, Quebec H7T 2P5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ville St-Laurent, Quebec H4T 1Z9, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ceske Budejovice, 370 01, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Cesky Krumlov, 381 01, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prague, 181 00, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Prerov, 750 02, Czech Republic
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Aalborg, 9000, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ballerup, 2750, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Vejle, 7100, Denmark
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ahmedabad, 380006, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Coimbatore, 641009, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Indore, 452002, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Jaipur, 302001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ludhiana, 141001, India
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Ponce, 00717-2075, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Rio Piedras, 00921, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    San Juan, 00917-3104, Puerto Rico
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Santurce, 00909, Puerto Rico
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Sep 2011 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Feb 2015, 3 years 5 months after primary completion. A results delay was requested in Nov 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2010
First posted
Jun 23, 2010
Start
Jun 2010
Primary completionActual
Sep 2011
CompletionActual
Jan 2012
Results delay requested
Nov 4, 2011
Results first posted
Feb 2, 2015
Last update
Feb 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01149421
Responsible party
Sponsor
First posted
Jun 23, 2010
Start date
Jun 2010
Primary completion
Sep 2011
Completion
Jan 2012
Results posted
Feb 2, 2015
Last update
Feb 2, 2015

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dulaglutide

Start the discussion